Circulating ceramides as biomarkers of cardiovascular disease: evidence from phenotypic and genomic studies.Citation formats

Standard

Circulating ceramides as biomarkers of cardiovascular disease: evidence from phenotypic and genomic studies. / McGurk, Kathryn; Keavney, Bernard; Nicolaou, Anna.

In: Atherosclerosis, Vol. 327, 06.05.2021, p. 18-30.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{8516c4cb36e247ed8ab639b288f3b7f6,
title = "Circulating ceramides as biomarkers of cardiovascular disease: evidence from phenotypic and genomic studies.",
abstract = "There is a need for new biomarkers of atherosclerotic cardiovascular disease (ACVD), the main cause of death globally. Ceramides, a class of potent bioactive lipid mediators, have signalling roles in apoptosis, cellular stress and inflammation. Recent studies have highlighted circulating ceramides as novel biomarkers of coronary artery disease, type-2 diabetes and insulin resistance. Ceramides are highly regulated by enzymatic reactions throughout the body in terms of their activity and metabolism, including production, degradation and transport. The genetic studies that have been completed to date on the main ceramide species found in circulation are described, highlighting the importance of DNA variants in genes involved in ceramide biosynthesis as key influencers of heritable, circulating ceramide levels. We also review studies of disease associations with ceramides and discuss mechanistic insights deriving from recent genomic studies. The signalling activities of ceramides in vascular inflammation and apoptosis, associations between circulating ceramides and coronary artery disease risk, type-2 diabetes and insulin resistance, and the potential importance of ceramides with regard to ACVD risk factors, such as blood pressure, lipoproteins and lifestyle factors, are also discussed.",
keywords = "Biomarkers, Ceramides, Genetics",
author = "Kathryn McGurk and Bernard Keavney and Anna Nicolaou",
note = "Funding Information: K.M. was supported by an MRC Doctoral Award (MR/K501311/1) and the University of Manchester President's Doctoral Scholarship. AN is supported in part by the NIHR Manchester Biomedical Research Centre and the BHF (PG/15/105/31906). BK is supported by a BHF Personal Chair. Publisher Copyright: {\textcopyright} 2021 The Author(s)",
year = "2021",
month = may,
day = "6",
doi = "https://www.atherosclerosis-journal.com/action/showPdf?pii=S0021-9150%2821%2900224-0",
language = "English",
volume = "327",
pages = "18--30",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Circulating ceramides as biomarkers of cardiovascular disease: evidence from phenotypic and genomic studies.

AU - McGurk, Kathryn

AU - Keavney, Bernard

AU - Nicolaou, Anna

N1 - Funding Information: K.M. was supported by an MRC Doctoral Award (MR/K501311/1) and the University of Manchester President's Doctoral Scholarship. AN is supported in part by the NIHR Manchester Biomedical Research Centre and the BHF (PG/15/105/31906). BK is supported by a BHF Personal Chair. Publisher Copyright: © 2021 The Author(s)

PY - 2021/5/6

Y1 - 2021/5/6

N2 - There is a need for new biomarkers of atherosclerotic cardiovascular disease (ACVD), the main cause of death globally. Ceramides, a class of potent bioactive lipid mediators, have signalling roles in apoptosis, cellular stress and inflammation. Recent studies have highlighted circulating ceramides as novel biomarkers of coronary artery disease, type-2 diabetes and insulin resistance. Ceramides are highly regulated by enzymatic reactions throughout the body in terms of their activity and metabolism, including production, degradation and transport. The genetic studies that have been completed to date on the main ceramide species found in circulation are described, highlighting the importance of DNA variants in genes involved in ceramide biosynthesis as key influencers of heritable, circulating ceramide levels. We also review studies of disease associations with ceramides and discuss mechanistic insights deriving from recent genomic studies. The signalling activities of ceramides in vascular inflammation and apoptosis, associations between circulating ceramides and coronary artery disease risk, type-2 diabetes and insulin resistance, and the potential importance of ceramides with regard to ACVD risk factors, such as blood pressure, lipoproteins and lifestyle factors, are also discussed.

AB - There is a need for new biomarkers of atherosclerotic cardiovascular disease (ACVD), the main cause of death globally. Ceramides, a class of potent bioactive lipid mediators, have signalling roles in apoptosis, cellular stress and inflammation. Recent studies have highlighted circulating ceramides as novel biomarkers of coronary artery disease, type-2 diabetes and insulin resistance. Ceramides are highly regulated by enzymatic reactions throughout the body in terms of their activity and metabolism, including production, degradation and transport. The genetic studies that have been completed to date on the main ceramide species found in circulation are described, highlighting the importance of DNA variants in genes involved in ceramide biosynthesis as key influencers of heritable, circulating ceramide levels. We also review studies of disease associations with ceramides and discuss mechanistic insights deriving from recent genomic studies. The signalling activities of ceramides in vascular inflammation and apoptosis, associations between circulating ceramides and coronary artery disease risk, type-2 diabetes and insulin resistance, and the potential importance of ceramides with regard to ACVD risk factors, such as blood pressure, lipoproteins and lifestyle factors, are also discussed.

KW - Biomarkers

KW - Ceramides

KW - Genetics

U2 - https://www.atherosclerosis-journal.com/action/showPdf?pii=S0021-9150%2821%2900224-0

DO - https://www.atherosclerosis-journal.com/action/showPdf?pii=S0021-9150%2821%2900224-0

M3 - Article

VL - 327

SP - 18

EP - 30

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

ER -